Comparison of Blood Loss Following Total Hip Arthroplasty With the Use of Three Thromboprophylactic Regimes: Dabigatran, Enoxaparin and Rivaroxaban.
- Conditions
- Hip OsteoarthritisBlood Loss
- Interventions
- Registration Number
- NCT02085824
- Lead Sponsor
- Centre of Postgraduate Medical Education
- Brief Summary
The purpose of this study is to determine which of the following drugs: enoxaparin, dabigatran and rivaroxaban causes least blood loss after total hip replacement (THR).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 60
- primary, end-stage hip osteoarthritis requiring total hip arthroplasty
- inflammatory arthropathies
- liver disorders
- neoplastic conditions
- clotting disorders
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description enoxaparin Enoxaparin enoxaparin 40mg 1x1 s.c. daily, once preoperatively and then daily for 28 days dabigatran dabigatran dabigatran 110 mg 1x1 p.o. postoperatively and then 1x2 p.o. for 27 days after the surgery rivaroxaban rivaroxaban rivaroxaban 10 mg 1x1 p.o. daily for 28 days after the surgery
- Primary Outcome Measures
Name Time Method Total blood loss by the 3rd postoperative day 3rd day postoperatively Measured for each individual. Measured according to the formula described by Nadler, Hidalgo and Bloch (Prediction of blood volume in normal human adults. Surgery 1962;51:224-32).
- Secondary Outcome Measures
Name Time Method Drop in the haemoglobin value between 3rd day postop and preoperative 3rd day postopertively Difference between haemoglobin on the 3rd postopertive day and day before operation
Wound healing disturbances according to the definition of Centers for Disease Control and Prevention 3 months postoperatively Wound healing disturbances - diagnosis to be made according to the definition of Centers for Disease Control and Prevention (Mangram, Horan, Pearson, Silver and Jarvis. Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol. 1999 Apr;20(4):250-78)
Trial Locations
- Locations (1)
Prof. A. Gruca Teaching Hospital, The Medical Centre of Postgraduate Education
🇵🇱Otwock, Woj. Mazowieckie, Poland